RGT 1.79% 28.5¢ argent biopharma limited

TH seems overkill but great news for MXC, real progress The...

  1. 1,078 Posts.
    lightbulb Created with Sketch. 122
    TH seems overkill but great news for MXC, real progress

    The registration and sale of a pharmaceutical product for the treatment of epilepsy presents a substantial commercial opportunity for MGC Pharmaceuticals. A registered pharmaceutical grade product has the potential to bring relief to millions of epilepsy sufferers across the globe. In Europe alone, there are close to 1 million children and young people with epilepsy and a further 2 million people aged between 20-64 suffering from epilepsy. Each year it is estimated that there are 130,000 new cases of epilepsy among children and adolescents in Europe1.
 
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.